全球病毒載體生產市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計病毒載體生產市場將從 2025 年的 27.6 億美元成長到 2034 年的 132.8 億美元，2026 年至 2034 年的複合年成長率為 19.06%。

受基因治療、細胞治療和疫苗研發計畫激增的推動，全球病毒載體生產市場正迅速擴張。病毒載體是將遺傳物質導入細胞的關鍵組成部分，在先進的生物製藥研究中不可或缺。基因治療臨床試驗和監管核准的增加顯著提升了生產需求。

成長要素包括載體工程技術的進步、生產流程擴充性以及製藥公司的積極投資。罕見遺傳疾病和癌症發生率的上升也是市場擴張的驅動力。此外，政府資助以及生物技術公司與合約開發組織（CDO）之間的策略合作正在增強全球產能。

隨著個人化醫療的日益普及，市場成長預計將加速。自動化、模組化生產設施以及上游工程下游製程的技術創新將提高效率並降低成本。隨著支持先進治療方法的法規結構不斷完善，病毒載體生產將繼續成為下一代生物製藥開發的基礎。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球病毒載體生產市場：依適應症分類

• 市場分析、洞察與預測
• 癌症
• 遺傳性疾病
• 感染疾病
• 其他疾病

第5章：全球病毒載體生產市場：依應用分類

• 市場分析、洞察與預測
• 基因治療
• 疫苗學

第6章：全球病毒載體生產市場：依病毒載體類型分類

• 市場分析、洞察與預測
• 腺病毒載體
• 慢病毒載體
• 逆轉錄病毒載體
• 腺結合病毒載體
• 其他病毒載體

第7章 全球病毒載體生產市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 亞太其他地區
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Oxford Biomedica
  • Andelyn Biosciences
  • Thermo Fisher Scientific Inc
  • Danaher Corporation
  • Charles River Laboratories
  • FinVector Oy
  • TAKARA HOLDINGS INC
  • Lonza
  • Avid Bioservices Inc
  • Novartis AG

The Viral Vector Production Market size is expected to reach USD 13.28 Billion in 2034 from USD 2.76 Billion (2025) growing at a CAGR of 19.06% during 2026-2034.

The Global Viral Vector Production Market is witnessing rapid expansion driven by the surge in gene therapy, cell therapy, and vaccine development programs. Viral vectors are critical components in delivering genetic material into cells, making them indispensable in advanced biopharmaceutical research. Increasing clinical trials and regulatory approvals for gene-based therapies are significantly boosting production demand.

Growth drivers include technological advancements in vector engineering, improved scalability of manufacturing processes, and strong investments from pharmaceutical companies. The rising prevalence of rare genetic disorders and cancer further supports market expansion. Additionally, government funding and strategic collaborations between biotech firms and contract development organizations enhance production capacity worldwide.

Looking ahead, the market is expected to grow at an accelerated pace as personalized medicine gains mainstream acceptance. Automation, modular manufacturing facilities, and innovations in upstream and downstream processing will improve efficiency and reduce costs. As regulatory frameworks evolve to support advanced therapies, viral vector production will remain a cornerstone of next-generation biopharmaceutical development.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Indication

• Cancer
• Genetic Disorders
• Infectious Diseases
• Other Diseases

By Application

• Gene Therapy
• Vaccinology

By Viral Vector Type

• Adenoviral Vectors
• Lentiviral Vectors
• Retroviral Vectors
• Adeno-Associated Viral Vectors
• Other Viral Vectors

COMPANIES PROFILED

• Oxford Biomedica, Andelyn Biosciences, Thermo Fisher Scientific Inc, Danaher Corporation, Charles River Laboratories, FinVector Oy, TAKARA HOLDINGS INC, Lonza, Avid Bioservices Inc, Novartis AG
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL VIRAL VECTOR PRODUCTION MARKET: BY INDICATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Indication
• 4.2. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Genetic Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Other Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL VIRAL VECTOR PRODUCTION MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Gene Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Vaccinology Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL VIRAL VECTOR PRODUCTION MARKET: BY VIRAL VECTOR TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Viral Vector Type
• 6.2. Adenoviral Vectors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Lentiviral Vectors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Retroviral Vectors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Adeno-Associated Viral Vectors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Other Viral Vectors Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL VIRAL VECTOR PRODUCTION MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Indication
  • 7.2.2 By Application
  • 7.2.3 By Viral Vector Type
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Indication
  • 7.3.2 By Application
  • 7.3.3 By Viral Vector Type
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Indication
  • 7.4.2 By Application
  • 7.4.3 By Viral Vector Type
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Indication
  • 7.5.2 By Application
  • 7.5.3 By Viral Vector Type
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Indication
  • 7.6.2 By Application
  • 7.6.3 By Viral Vector Type
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL VIRAL VECTOR PRODUCTION INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Oxford Biomedica
  • 9.2.2 Andelyn Biosciences
  • 9.2.3 Thermo Fisher Scientific Inc
  • 9.2.4 Danaher Corporation
  • 9.2.5 Charles River Laboratories
  • 9.2.6 FinVector Oy
  • 9.2.7 TAKARA HOLDINGS INC
  • 9.2.8 Lonza
  • 9.2.9 Avid Bioservices Inc
  • 9.2.10 Novartis AG